AdAlta (1AD) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free 1AD Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLong Shortz with AdAlta: Strengthening bonds in the fight against cancermsn.com - April 8 at 5:54 AMAdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapymsn.com - April 7 at 10:42 PMAdAlta delivers positive Phase I Extension Study results for AD-214finance.yahoo.com - March 8 at 2:28 PMScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial resultsmsn.com - March 8 at 12:56 AMLeeds - Weather warnings issuedbbc.com - February 15 at 11:31 PMCountdown on to AdAlta trial results as biotech advances partner discussionsmsn.com - February 11 at 11:26 PMAdAlta Insiders Placed Bullish Bets Worth AU$850.2kfinance.yahoo.com - February 4 at 6:23 PMAdAlta advancing partnering programs as AD-214 participants receive final dosemsn.com - January 22 at 10:08 PMAdalta Ltd (1AD)es.investing.com - January 9 at 8:55 PMWhat’s in store for 2024: AdAltamsn.com - January 4 at 9:25 AMMoney Talks: Keep an eye on these tasty precious metal and biotech plays in 2024msn.com - December 28 at 7:30 AMLong Shortz with AdAlta: How the company has potentially broken the malaria life cyclemsn.com - December 19 at 11:22 PM‘World first’: AdAlta’s i-body platform a breakthrough for malaria treatmentmsn.com - December 18 at 7:58 PMAdAlta on track for trial readout in Q1 2024 after $1.65m cap raisemsn.com - December 13 at 10:42 PM‘Best place we’ve ever been’: AdAlta looks to monetise lead asset in 2024msn.com - November 30 at 8:18 PMASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra Healthmsn.com - November 20 at 8:41 PMAdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risksmsn.com - November 20 at 8:41 PMAdAlta raises $1.65 million in oversubscribed placement to support clinical study and partner discussionsproactiveinvestors.com.au - November 18 at 3:45 PMIt's Probably Less Likely That AdAlta Limited's (ASX:1AD) CEO Will See A Huge Pay Rise This Yearfinance.yahoo.com - November 15 at 5:52 PMAdAlta closes oversubscribed $1.65 million raiseproactiveinvestors.com.au - November 7 at 8:24 PMAdAlta making material progress on partnering talksproactiveinvestors.com.au - October 22 at 7:47 PMAdAlta to present lead product AD-214 at MPGPCR 2023 pharmacology conferenceau.investing.com - October 19 at 12:41 AMAdAlta receives $2.3 million FY23 R&D refund; extends loan repayment termsproactiveinvestors.com.au - October 17 at 8:01 PMAdAlta says new AD-214 dosing models enhance partnering potentialfinance.yahoo.com - September 26 at 7:33 PMAdAlta clinical dose simulations of AD-214 support target intravenous dose regimeproactiveinvestors.com.au - September 24 at 11:40 PMAdAlta completes enrolment for AD-214 fibrosis safety trialproactiveinvestors.com.au - September 20 at 10:40 PMAdAlta finalises healthy volunteer enrolment for safety trial of fibrosis candidate AD-214proactiveinvestors.com.au - September 19 at 10:46 PMAdAlta to Present at August 24th Virtual Investor Summitfinance.yahoo.com - August 16 at 3:42 PMAdAlta back in the clinic with AD-214finance.yahoo.com - August 8 at 11:01 AMAdAlta doses participants with potential fibrosis therapy AD-214 in return to clinicau.investing.com - August 3 at 8:36 PMAdAlta eyes AD-214 Phase I extension studyproactiveinvestors.com.au - July 18 at 12:05 AMAdAlta raises $1.87 million through oversubscribed shortfall facility; funds for lead asset AD-214proactiveinvestors.com.au - July 12 at 11:30 PMAdAlta links AD-214 results with efficacy thanks to new datafinance.yahoo.com - July 7 at 3:55 PMAdAlta reveals new data supporting potential efficacy of AD-214 for fibrotic diseasesproactiveinvestors.com.au - July 6 at 10:15 PMAdAlta extends I-body trial following ethics approvalproactiveinvestors.com.au - June 29 at 12:01 AM1AD.AX - AdAlta Limitedau.finance.yahoo.com - June 27 at 12:17 PMAdAlta to present at June 1 Virtual Investor Summitfinance.yahoo.com - May 30 at 10:47 AMAdAlta secures A$1.28 million in rights offer to advance AD-214proactiveinvestors.com.au - May 24 at 11:41 PMAdAlta on track to raise $3.15 million to fund early return to clinic for AD-214proactiveinvestors.com.au - May 24 at 11:41 PMOrphan drug designation has a direct impact on drug pricing for these pharma playersmsn.com - May 21 at 7:10 PMAdAlta to support early return to clinical trials of AD-214 with rights offerfinance.yahoo.com - May 1 at 2:51 PMAdAlta Ltd seeks $3.5 million to support early return to clinical trials of AD-214proactiveinvestors.com.au - April 27 at 11:53 PMCRITERION: The ASX cancer fighters with a sting in their treatment tailsmsn.com - April 26 at 3:01 PMAdAlta Limited (1AD.AX)ca.finance.yahoo.com - April 2 at 12:01 PMAdAlta First Half 2023 Earnings: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022)finance.yahoo.com - March 3 at 9:35 PMAdAlta CEO highlights strong progress across CAR-T and AD-214 programsproactiveinvestors.com.au - February 28 at 1:02 AMAdAlta welcomes long-term support from Yuuwa Capital investorsproactiveinvestors.com.au - February 17 at 12:15 AMAdAlta research collaborators publish paper suggesting use for i-body as therapy for osteoporosisproactiveinvestors.com.au - January 24 at 11:23 PMAdAlta welcomes substantial shareholders as Yuuwa Capital completes end-of-fund wind-up and exitproactiveinvestors.com.au - January 23 at 8:42 PMAdAlta granted second Japanese patent for lead i-body AD-214proactiveinvestors.com.au - January 9 at 7:56 PM Get AdAlta News Delivered to You Automatically Sign up to receive the latest news and ratings for 1AD and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here 1AD Media Mentions By Week 1AD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. 1AD News Sentiment▼0.000.43▲Average Medical News Sentiment 1AD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. 1AD Articles This Week▼00▲1AD Articles Average Week Get AdAlta News Delivered to You Automatically Sign up to receive the latest news and ratings for 1AD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ARTLW News Today ASCLF News Today AWKNF News Today AXIM News Today BRRGF News Today BCTXW News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:1AD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdAlta Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
